MDT-AP-0532
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 4.32
- os_event
- true
- age_years
- 3.16
- sex
- M
- new_clusters
- C2
- umap1_2d
- 2.136249646
- umap2_2d
- 0.078134435
- umap1_3d
- -0.963941169
- umap2_3d
- -2.387573452
- umap3_3d
- -1.046693655
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.670
- MYC_TARGETS_V1+0.510
- TNFA_SIGNALING_VIA_NFKB+0.510
- MTORC1_SIGNALING+0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.410
- INFLAMMATORY_RESPONSE+0.400
- ANGIOGENESIS+0.390
- IL6_JAK_STAT3_SIGNALING+0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.340
Top 10 suppressed
- PROTEIN_SECRETION-0.220
- BILE_ACID_METABOLISM-0.210
- UV_RESPONSE_DN-0.170
- MITOTIC_SPINDLE-0.150
- HEDGEHOG_SIGNALING-0.080
- WNT_BETA_CATENIN_SIGNALING-0.030
- NOTCH_SIGNALING-0.010
- APICAL_JUNCTION+0.010
- PEROXISOME+0.010
- SPERMATOGENESIS+0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0370 | Med | Medulloblastoma | 0.935 |
| 2 | MDT-AP-2001 | Med | Medulloblastoma | 0.909 |
| 3 | X3a5c813b.6c47.49aa.916c.bcddbafdd54b | — | cohortA1 | 0.898 |
| 4 | MDT-AP-2036 | Med | Medulloblastoma | 0.897 |
| 5 | MDT-AP-2118 | Med | Medulloblastoma | 0.891 |
| 6 | 8DA59514-8B25-493E-B226-818F2521B5D5 | — | — | 0.890 |
| 7 | MDT-AP-1185 | Med | Medulloblastoma | 0.885 |
| 8 | TCGA-66-2765-01A-01R-0851-07 | — | cohortSQ1 | 0.881 |
| 9 | SRR11296801 | — | — | 0.877 |
| 10 | SRR8942992 | — | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.670 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.510 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.430 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.410 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.360 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.340 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.320 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| APOPTOSIS | 0.310 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.310 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |